It's experimental therapy, but some say it comes pretty close to curing the common cold. Researchers at the University of Virginia have developed a three drug treatment they say gives the cold a double blow.
Blow 1 is a nasal spray with the drug interferon which knocks out the virus which causes the infection. Two other drugs deliver the second blow -- an antihistamine and ibuprofen block the body's response to the infection, which is the cause of a runny nose and other cold symptoms.
In a double blind study of 150 people, those who received the drug trio had up to 73% fewer cold symptoms. The cold combo therapy has been licensed and is in development for commercial use. The study was funded by the University of Virginia and the new treatment is licensed to Coldcure, Inc., in Richmond for development into commercial use.
The study was conducted at the University of Virginia and is published in the current online issue of the Journal of Infectious Diseases. In March, an advisory panel voted unanimously against recommending that the Food and Drug Administration approval for the first anti-viral cold medication. The drug's developer, Viropharma and marketing partner Aventis Pharmaceuticals, had hoped to have it on the market this fall under the brand name Picovir.
Obesity and high blood pressure may play a much greater role in sudden cardiac arrest among young people than previously thought, a new study suggests.
Flu continues to ravage the United States in one of the worst flu seasons in recent years. And the ineffectiveness of this year's flu vaccine is partly to blame.